Paolo Tarantino: The SERENA-2 phase 2 trial of camizestrant vs fulvestrant is out
Paolo Tarantino, Research Fellow at The Dana-Farber Cancer Institute, shared on X:
“The SERENA-2 phase 2 trial of camizestrant vs fulvestrant is out in The Lancet Oncology.
Cami doubled PFS in ET-pretreated MBC, with most benefit in patients with ESR1 mutations. SERENA-4 and -6 phase 3 trials ongoing.
Great editorial by Kristina Fannucci and Erica Mayer.”
Authors: Mafalda Oliveira, Denys Pominchuk, Prof Zbigniew Nowecki, Erika Hamilton, Yaroslav Kulyaba, Timur Andabekov, Prof Yevhen Hotko, Tamar Melkadze, Prof Gia Nemsadze, Prof Patrick Neven, Vladimir Vladimirov, Claudio Zamagni, Hannelore Denys, Frédéric Forget, Zsolt Horvath, Alfiya Nesterova, Maxine Ajimi, Bistra Kirova, Teresa Klinowska, Justin P O Lindemann, Delphine Lissa, Alastair Mathewson, Christopher J Morrow, Zuzana Traugottova, Ruaan van Zyl, Ekaterine Arkania.
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023